Author:
Takamizawa Shigemasa,Katsuya Yuki,Chen Yi-Ning,Mizuno Takaaki,Koyama Takafumi,Sudo Kazuki,Yoshida Tatsuya,Kondo Shunsuke,Iwasa Satoru,Yonemori Kan,Shimizu Toshio,Yamamoto Noboru,Suzuki Shigenobu
Abstract
SummaryOcular toxicities arising from anti-cancer drugs occur sporadically and are sometimes underestimated because they are not life-threatening. Reports focusing on ocular toxicities from cancer therapy are limited. We investigated the detailed progress of ocular toxicities of anti-cancer drugs including first-in-class ones. A retrospective review of medical records was conducted for patients who were involved in early phase clinical trials with scheduled ophthalmologic examinations according to their protocols between January 2014 and August 2021. Patients with ocular toxicity suspected to be related to the investigational drugs in the ophthalmic examination were investigated in detail. In total, 37 ocular toxicities related to investigational drugs occurred in 7.6% of patients (33/434). The median age of the 33 patients was 61 years (range, 33–76 years), and 20 were male. Causal drugs with a high incidence of ocular toxicities were HSP90 inhibitors and FGFR inhibitors. Retinopathy was most frequent, while conjunctivitis, dry eye, keratitis, keratopathy, and uveitis were also observed. Dim vision as a subjective finding was a unique adverse event. Most patients developed ocular toxicities even though their dose was below the drug’s maximum tolerated dose. Except for one case, all ocular toxicities occurred bilaterally. About 60% (22/37) of ocular toxicity cases needed a temporary hold of the drug. All except for three cases fully recovered. This study reported the risks and timing of the onset of a variety of ocular toxicities of anti-cancer drugs, which were fundamentally controllable. (Trial registration number. Retrospectively registered)
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference6 articles.
1. Fortes BH, Tailor PD, Dalvin LA (2021) Ocular toxicity of targeted anticancer agents. Drugs 81:771–823
2. Facchinetti F, Hollebecque A, Bahleda R et al (2020) Facts and new hopes on selective FGFR inhibitors in solid tumors. Clin Cancer Res 26:764–774
3. U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed 2 Dec 2022
4. Yamamoto N, Ryoo BY, Keam B et al (2020) A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies. Invest New Drugs 38:445–456
5. Koyama T, Shimizu T, Iwasa S et al (2020) First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci 111:571–579
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献